Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention - PubMed
Review
. 2012 Nov;295(11):1837-50.
doi: 10.1002/ar.22578. Epub 2012 Oct 8.
Affiliations
- PMID: 23045231
- PMCID: PMC3596108
- DOI: 10.1002/ar.22578
Review
Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention
Jochen Schacht et al. Anat Rec (Hoboken). 2012 Nov.
Abstract
This review introduces the pathology of aminoglycoside antibiotic and the cisplatin chemotherapy classes of drugs, discusses oxidative stress in the inner ear as a primary trigger for cell damage, and delineates the ensuing cell death pathways. Among potentially ototoxic (damaging the inner ear) therapeutics, the platinum-based anticancer drugs and the aminoglycoside antibiotics are of critical clinical importance. Both drugs cause sensorineural hearing loss in patients, a side effect that can be reproduced in experimental animals. Hearing loss is reflected primarily in damage to outer hair cells, beginning in the basal turn of the cochlea. In addition, aminoglycosides might affect the vestibular system while cisplatin seems to have a much lower likelihood to do so. Finally, based on an understanding the mechanisms of ototoxicity pharmaceutical ways of protection of the cochlea are presented.
Copyright © 2012 Wiley Periodicals, Inc.
Figures

Explants of the postnatal mouse organ of Corti were cultured for 72 h with or without 3.5 μM gentamicin, then fixed and stained for actin with rhodamine phalloidin (Chen et al., 2009). A: Incubation without drug. The red stain outlines the orderly arrangement of the three rows of outer hair cells (OHC1, OHC2, OHC3) and one row of inner hair cells (IHC). B, C, D: Incubation with gentamicin. The middle section of the organ of Corti (B) shows a few missing outer hair cells, mostly in row 1. Further towards the base (C), more damage is evident. The basal segment (D) has essentially lost all outer hair cells while inner hair cells remain. Experiment and photo courtesy of Dr. Naoki Oishi.

Administration of NOX3 siRNA reduces immunolabeling of NOX3 and p-STAT1. Rats were injected trans-tympanically with scrambled or NOX3 siRNA 48 h prior to a cisplatin injection of 11 mg/kg i.p. Three days later cochleae were removed and processed for immunohistochemistry. NOX3 siRNA reduced both the basal and cisplatin-stimulated p-STAT1 (green) and NOX3 (red) immunoreactivity in various regions of the cochlea. NOX3 and p-STAT1 immunolabeling co-localized, demonstrated by the merged images (yellow). OHC, outer hair cells; SVA, stria vascularis; SG, spiral ganglion; SL, spiral ligament. Scale bars (lower right) represent 50 μm. The images shown are a representative of three independent experiments showing similar results. (This figure was published as supplementary figure 4 in Kaur et al, 2011).

(a) Bar graphs depict ABR threshold measured in rats 72 h after treatment with cisplatin (11 mg/kg i.p.) which was begun 48 h after transtympanic injection of scrambled RNA or STAT1 siRNA (0.9 ug). (b) Scanning electron microscopy of the basal turn of the cochlea of these rats. The representative figure demonstrates significant damage to outer hair cells (white arrows) by cisplatin which is prevented by pretreatment with STAT1 siRNA. (c) Quantitation of the scanning electron microscopy data. Bar graphs depict mean +/− S.E.M. The asterisks indicate statistically significant difference between the STAT1 siRNA + cisplatin group (**) and scramble + cisplatin treatment group and the scramble-treated versus the scramble + cisplatin group (p <0.05, n = 6). (This figure was published as Figure 4 in Kaur et al, (2011).
Similar articles
-
Rybak LP, Ramkumar V. Rybak LP, et al. Kidney Int. 2007 Oct;72(8):931-5. doi: 10.1038/sj.ki.5002434. Epub 2007 Jul 25. Kidney Int. 2007. PMID: 17653135 Review.
-
Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.
Kros CJ, Steyger PS. Kros CJ, et al. Cold Spring Harb Perspect Med. 2019 Nov 1;9(11):a033548. doi: 10.1101/cshperspect.a033548. Cold Spring Harb Perspect Med. 2019. PMID: 30559254 Free PMC article. Review.
-
Ototoxicity: therapeutic opportunities.
Rybak LP, Whitworth CA. Rybak LP, et al. Drug Discov Today. 2005 Oct 1;10(19):1313-21. doi: 10.1016/S1359-6446(05)03552-X. Drug Discov Today. 2005. PMID: 16214676 Review.
-
Sound preconditioning therapy inhibits ototoxic hearing loss in mice.
Roy S, Ryals MM, Van den Bruele AB, Fitzgerald TS, Cunningham LL. Roy S, et al. J Clin Invest. 2013 Nov;123(11):4945-9. doi: 10.1172/JCI71353. J Clin Invest. 2013. PMID: 24216513 Free PMC article.
-
Pharmacological intervention in the field of ototoxicity.
Laurell G. Laurell G. HNO. 2019 Jun;67(6):434-439. doi: 10.1007/s00106-019-0663-1. HNO. 2019. PMID: 30993373 Free PMC article. Review.
Cited by
-
Taylor RR, Jagger DJ, Saeed SR, Axon P, Donnelly N, Tysome J, Moffatt D, Irving R, Monksfield P, Coulson C, Freeman SR, Lloyd SK, Forge A. Taylor RR, et al. Neurobiol Aging. 2015 Jun;36(6):2068-84. doi: 10.1016/j.neurobiolaging.2015.02.013. Epub 2015 Feb 17. Neurobiol Aging. 2015. PMID: 25818177 Free PMC article.
-
[Progress in genetic susceptibility to aminoglycoside-induced deafness].
Tian Y, Chen Z. Tian Y, et al. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Apr;35(4):375-379. doi: 10.13201/j.issn.2096-7993.2021.04.021. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021. PMID: 33794642 Free PMC article. Review. Chinese.
-
Hair cell toxicology: With the help of a little fish.
Barrallo-Gimeno A, Llorens J. Barrallo-Gimeno A, et al. Front Cell Dev Biol. 2022 Dec 13;10:1085225. doi: 10.3389/fcell.2022.1085225. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36582469 Free PMC article. Review.
-
Kinoshita M, Fujimoto C, Iwasaki S, Kondo K, Yamasoba T. Kinoshita M, et al. Pharmaceutics. 2023 Feb 2;15(2):493. doi: 10.3390/pharmaceutics15020493. Pharmaceutics. 2023. PMID: 36839815 Free PMC article.
-
Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients.
Rivetti S, Romano A, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Rivetti S, et al. Pharmaceuticals (Basel). 2023 Sep 25;16(10):1353. doi: 10.3390/ph16101353. Pharmaceuticals (Basel). 2023. PMID: 37895824 Free PMC article. Review.
References
-
- Alam SA, Ikeda K, Oshima T, Suzuki M, Kawase T, Kikuchi T, Takasaka T. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res. 2000;141:28–38. - PubMed
-
- Battaglia A, Pak K, Brors D, Bodmer D, Frangos JA, Ryan AF. Involvement of ras activation in toxic hair cell damage of the mammalian cochlea. Neuroscience. 2003;122(4):1025–1035. - PubMed
-
- Behnoud F, Davoudpur K, Goodarzi MT. Can aspirin protect or at least attenuate gentamicin ototoxicity in humans? Saudi Med J. 2009;30(9):1165–1169. - PubMed
-
- Benedetti Panici P, Greggi S, Scambia G, Baiocchi G, Lomonaco M, Conti G, Mancuso S. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Int J Gynecol Cancer. 1993;3:44–53. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical